An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Eli Lilly’s CEO, David Ricks, said that tirzepatide — a weight-loss and diabetes drug sold as Mounjaro for diabetes and Zepbound for weight loss — will become the best‑selling drug ever. That’s a big, confident prediction from the company that makes the drug. The news is mainly a statement from the company’s leadership, not a new clinical trial or government announcement. Tirzepatide is a synthetic medication that copies signals our body uses to control blood sugar and appetite. In plain terms, it acts like two natural gut hormones at once: one that helps control insulin and blood sugar, and another that tells your brain you’re full and slows how fast food leaves your stomach. Because it targets both pathways, people taking it often lose more weight and have bigger improvements in blood sugar than with some older medicines that affect only one hormone. What the research has shown so far comes from clinical trials and prescribing data. Large trials in people with obesity or type 2 diabetes found substantial weight loss—often in the double-digit percentages of body weight over months—and better blood-sugar control compared with placebo or some older drugs. Those are carefully run studies with hundreds to thousands of participants. The CEO’s claim about being the best‑selling drug is not a study result; it’s a business forecast grounded in strong sales and growing demand, but it’s not the same as proof of new medical benefits. Why this matters for everyday people is twofold. For patients with type 2 diabetes or obesity, tirzepatide offers a powerful new option that may help with weight loss and blood-sugar control when other medicines haven’t worked well. For the broader public, the drug’s popularity is reshaping medical care, insurance coverage, and how people think about treating obesity — which many experts argue should be treated like a medical condition, not just a lifestyle issue. Doctors, insurers, employers, and regulators will all be watching because the drug’s cost and demand could affect access and healthcare budgets. There are important caveats and risks. Common side effects include nausea, vomiting, diarrhea, and constipation; these often improve over time but can be unpleasant. Long-term safety beyond the trial durations is still being studied. Not everyone can or should take tirzepatide — people with certain medical histories, like a family history of a specific type of thyroid cancer, may be advised against it. Pricing and insurance coverage vary, and the CEO’s sales prediction doesn’t change the fact that access depends on approvals and who pays for the drug. Bottom line: The company thinks tirzepatide will become hugely successful, and clinical trials do show it can produce significant weight loss and blood-sugar improvements, but the CEO’s sales claim is a business prediction rather than new scientific evidence, and questions about long-term safety, access, and cost remain.
Source: BigGo Finance